



The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF)



Harold A. Sackeim^{a,*}, Scott T. Aaronson^b, Mark T. Bunker^c, Charles R. Conway^d,
Mark A. Demitrack^e, Mark S. George^f, Joan Prudic^g, Michael E. Thase^h, A. John Rush^{i,j,k}

^a Departments of Psychiatry and Radiology, Columbia University, New York, NY, USA

^b Sheppard Pratt Health System and Department of Psychiatry, University of Maryland, Baltimore, MD, USA

^c LivaNova PLC, Houston, TX, USA

^d Department of Psychiatry, Washington University, St. Louis, MO, USA

^e Trevena, Inc., Chesterbrook, PA, USA

^f Departments of Psychiatry, Neurology, and Neuroscience, Medical University of South Carolina, Charleston, SC, USA

^g New York State Psychiatric Institute and Department of Psychiatry, Columbia University, New York, NY, USA

^h Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

ⁱ Duke-NUS Medical School, Singapore

^j Duke University, Durham, NC, USA

^k Texas Tech University, Permian Basin, TX, USA

ARTICLE INFO

Keywords:

Antidepressant treatment resistance

Pharmacotherapy

Brain stimulation

Psychotherapy

Major depressive episode

Treatment-resistant depression

ABSTRACT

There is considerable diversity in how treatment-resistant depression (TRD) is defined. However, every definition incorporates the concept that patients with TRD have not benefited sufficiently from one or more adequate trials of antidepressant treatment. This review examines the issues fundamental to the systematic evaluation of antidepressant treatment adequacy and resistance. These issues include the domains of interventions deemed effective in treatment of major depressive episodes (e.g., pharmacotherapy, brain stimulation, and psychotherapy), the subgroups of patients for whom distinct adequacy criteria are needed (e.g., bipolar vs. unipolar depression, psychotic vs. nonpsychotic depression), whether trials should be rated dichotomously as adequate or inadequate or on a potency continuum, whether combination and augmentation strategies require specific consideration, and the criteria used to evaluate the adequacy of treatment delivery (e.g., dose, duration), trial adherence, and clinical outcome. This review also presents the Antidepressant Treatment History Form: Short-Form (ATHF-SF), a completely revised version of an earlier instrument, and details how these fundamental issues were addressed in the ATHF-SF.

1. Introduction

In recent years there has been intense interest in treatment-resistant depression (TRD) (Berlim and Turecki, 2007b; Ruhe et al., 2012). Earlier estimates suggested that two-thirds of patients in a major depressive episode (MDE) have substantial improvement following their first antidepressant medication trial (Klein et al., 1980; Souery et al., 1999). The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (Rush et al., 2004) challenged this perspective. In a large sample without a history of adequate antidepressant treatment failure in the current episode, approximately 30% remitted following treatment with citalopram. Non-remitters received up to three additional trials of antidepressant treatment (Rush et al., 2006b). The

likelihood of acute benefit decreased with each subsequent trial, and, if remission was obtained, the likelihood of relapse increased. For example, in STAR*D the probability of both remitting and sustaining that remission for a year was less than 5% in patients receiving their third antidepressant treatment (Conway et al., 2017). This prospective study and similar data (Fife et al., 2017; Mahlich et al., 2018; Rizvi et al., 2014; Saveanu et al., 2015; Thomas et al., 2013) have led to the estimate that approximately one-third of patients in a MDE are characterized by TRD (Berlim and Turecki, 2007b; Cepeda et al., 2018; Fava, 2003; Thase, 2011). TRD is associated with increased morbidity and mortality (Banankhah et al., 2015; Reutfors et al., 2018; Souery et al., 2007), increased medical and psychiatric health care costs (Amos et al., 2018; Kubitz et al., 2013; Lepine et al., 2012; Mahlich et al.,

* Corresponding author. 2124, Moselem Springs Road, Fleetwood, PA, 19522, USA.

E-mail address: has1@columbia.edu (H.A. Sackeim).

<https://doi.org/10.1016/j.jpsychires.2019.03.021>

Received 18 December 2018; Received in revised form 11 March 2019; Accepted 21 March 2019

0022-3956/© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Table 1
Essential features of assessment instruments and models of treatment-resistant depression.

	Antidepressant Treatment History Form (ATHF) (Sackeim, 2001; Sackeim et al., 1990)	Thase and Rush Staging Model (Thase and Rush, 1995, 1997)	European Staging Model (European Medicines Agency, 2013; Souery et al., 1999)	Massachusetts General Hospital Staging Model (MGH-s) (Fava, 2003) and the Antidepressant Treatment Response Questionnaire (ATRQ) (Desseilles et al., 2011)	Maudsley Staging Model (Fekadu et al., 2009; van Belkum et al. (2018))	Conway et al. Staging Model (Conway et al., 2017)	Antidepressant Treatment History Form: Short Form (ATHF-SF)
Explicit Operational Criteria	Yes	No	No	Yes	Yes	No	Yes
Inclusion of Non-pharmacological interventions	ECT only	ECT only	None	ECT only	ECT only	Unspecified brain stimulation and psychotherapies	Multiple brain stimulation and psychotherapy interventions
Separate Criteria for Depression Subgroups	Bipolar vs. Unipolar MDE; Psychotic vs. Nonpsychotic MDE	No	No	No	No	No	Bipolar vs. Unipolar MDE; Psychotic vs. Nonpsychotic MDE
Criteria for Combination and/or Augmentation Trials	Yes	No	Yes	Yes	Yes	No	Yes
Additional information used for TRD score	No	No	Duration of treatment	No	No	Duration of episode; Baseline symptom severity	No

2018; Olfson et al., 2018; Russell et al., 2004), and markedly reduced quality of life (Johnston et al., 2018; Mrazek et al., 2014).

2. Definitions and models of treatment-resistant depression

The assessment of resistance to antidepressant treatment impacts on clinical decision making, the quality of research, and public health policy (Gaynes et al., 2018; Ruhe et al., 2012). Regulatory agencies like the FDA have increasingly labelled medications and medical devices as indicated for different levels of TRD, typically defined in terms of the number of “failed adequate” trials (Center for Drug Evaluation and Research (CDER), 2018). Recommendation of new therapeutic regimens and prognostic information conveyed to patients by treatment providers are strongly influenced by their assessment of prior treatment history. In research, inclusion/exclusion criteria now commonly stipulate the range of treatment resistance that characterizes samples. The reliable assessment of TRD is also fundamental to investigation of its neurobiology, phenomenological correlates, treatment options, and prognostic significance.

Various approaches have been taken to define, categorize, and/or quantify degree of treatment resistance (see Table 1) (Berlim and Turecki, 2007a, b; Hazari et al., 2013; Ruhe et al., 2012; Trevino et al., 2014). Most approaches are categorical. For instance, in line with the staged model originally proposed by Thase and Rush (1995, 1997), the European Medicines Agency stated that “a patient has been considered suffering from TRD when consecutive treatment with two products of different pharmacological classes, used for a sufficient length of time at an adequate dose, fail to induce a clinically meaningful effect (inadequate response)” (European Medicines Agency, 2013). However, TRD definitions vary in whether they require “failed” trials from 1 or more classes of pharmacological treatment, the number of such failed trials, the definition of what constitutes a failed trial, and whether they include brain stimulation interventions, such as electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS), or psychotherapies as potential adequate failed trials (Berlim and Turecki, 2007a; Demyttenaere and Van Duppen, 2019; Gaynes et al., 2018; Ruhe et al., 2012). Some staging models prioritize particular treatment strategies. For example, the Massachusetts General Hospital (MGH) (Fava, 2003) and Maudsley (Fekadu et al., 2009) staging models give extra weight if patients had not benefited sufficiently from adequate pharmacological augmentation trials, as well as ECT. Some approaches evaluate dimensions that extend beyond the patient’s treatment history. In addition to the number of failed adequate antidepressant trials, the Maudsley model weights baseline illness severity and duration of illness in producing an overall score of the degree of treatment resistance (Fekadu et al., 2009; van Belkum et al., 2018). A Dutch extension of the Maudsley staging model also includes degree of functional impairment, co-morbid anxiety, and psychosocial stressors in quantifying TRD (Peeters et al., 2016).

Undoubtedly, heterogeneity in the definitions and metrics used to identify and quantify TRD impedes progress (Berlim and Turecki, 2007a; Demyttenaere and Van Duppen, 2019; Gaynes et al., 2018; Hazari et al., 2013; Ruhe et al., 2012). However, at their core, each approach to defining and measuring TRD requires assessment of the whether individual antidepressant treatment trials were adequately administered and resulted in insufficient clinical benefit. The models differ principally in how many “failed adequate” trials they require for classification, their stipulations regarding the pharmacological classes of these trials, and the extra weight, if any, given particular treatment strategies (pharmacological augmentation, ECT).

3. Antidepressant Treatment History Form (ATHF)

The standardization of psychiatric diagnosis through the use of structured interviews and objective criteria was a major advance. Far less attention, however, has been paid to standardizing the assessment

Table 2
ATHF rating criteria for antidepressant treatments.

Rating	Criteria
0	No treatment or medication with known psychotropic action
1	Any medication < 4 weeks or < minimum adequate daily dose (or blood level) ^a ECT: 1–3 treatments
2	Any medication ≥ 4 weeks at less than the minimum adequate daily dose or blood level ^a ECT: 4–6 treatments
3	Any medication ≥ 4 weeks and higher than minimum adequate daily dose or blood level ^a For psychotic MDE: combination with an antipsychotic (≥ 400 CPZ equivalents) for ≥ 3 weeks ECT: 7–9 unilateral treatments
4	Any medication ≥ 4 weeks at higher dose or blood level or any medication at level 3 augmented with lithium ≥ 2 weeks ^a For psychotic MDE: combination with an antipsychotic (≥ 400 CPZ equivalents) for ≥ 3 weeks ECT: 10–12 unilateral treatments; 7–9 bilateral treatments
5	Any medication at level 4 augmented with lithium ≥ 2 weeks ^a For psychotic MDE: combination with an antipsychotic (≥ 400 CPZ equivalents) for ≥ 3 weeks ECT: ≥ 13 unilateral treatments; ≥ 10 bilateral treatments

ATHF = Antidepressant Treatment History Form; Minimum adequate daily dosages are provided for all medications that can be rated “2” or higher. A higher dose range is also provided for ratings of “4” or “5”.

of antidepressant treatment history despite its importance in treatment selection and prognosis, and its public health implications (Philip et al., 2010; Ruhe et al., 2012; Thase and Rush, 1995; Wijeratne and Sachdev, 2008). The ATHF (Sackeim, 2001) has been perhaps the most widely used instrument to systematically assess antidepressant treatment trials and characterize treatment resistance. This instrument provides explicit criteria for evaluating the adequacy of treatment with pharmacological and brain stimulation interventions deemed to be effective in MDE. Of instruments with a similar purpose (e.g., the MGH Antidepressant Treatment Response Questionnaire [ATRQ]) (Desseilles et al., 2011), the ATHF is unique in providing separate criteria for unipolar and bipolar MDE, as well as psychotic and non-psychotic MDE (Hazari et al., 2013).

The ATHF uses a 5-point scale to rate each antidepressant trial (see Table 2). Scores of 1 or 2 apply to “inadequate” trials, in which the treatment was given in insufficient dose or duration. Scores of 3 and above indicate different degrees of treatment resistance. For pharmacological agents, trials with scores of 4 or 5 connote either use of a medication above the established minimally effective dose (score of 3) or the use of specific augmentation strategies (e.g., an antidepressant medication plus lithium). The ATHF also requires judgment regarding adherence and clinical outcome. Patients are not considered as resistant to a treatment if they did not receive it due to non-adherence. Likewise, the concept of resistance or a “failed adequate trial” requires that patients manifest insufficient clinical improvement on the specific regimen adhered to at sufficient dose and duration. To receive a score of 3 or higher, the ATHF requires that the clinical improvement in the trial be below the level associated with response. Response is usually defined as a 50% reduction in MDE symptom severity, and corresponds to a judgment that substantial clinical improvement was obtained (Frank et al., 1991; Rush et al., 2006a).

The ATHF produces summary scores for the total number of antidepressant trials attempted, the number of “failed adequate trials” (ratings of 3 or higher), the rating of the most potent trial (1–5), and the total potency across all trials. Since the ATHF scores each trial independently, and also groups pharmacological treatments into specific classes (e.g., TCA, MAOI, etc.), the ATHF can be used to derive any of the various TRD definitions and metrics that have been proposed.

The ATHF was first developed in studies of ECT, where retrospective assessment of the degree of medication resistance was found in some, but not all, studies to prospectively predict both short-term ECT outcome (Dombrowski et al., 2005; Heijnen et al., 2010; Prudic et al., 1996; Prudic et al., 1990; Rasmussen et al., 2007; Sackeim et al., 2009; Sackeim et al., 2000; Sackeim et al., 2008; van den Broek et al., 2004) and likelihood of postECT relapse (Prudic et al., 2013; Rasmussen et al., 2009; Sackeim et al., 1990, 2001a). The ATHF was then applied in a

variety of studies with other brain stimulation interventions, both to specify minimal and maximal levels of treatment resistance in samples and as a predictor of outcome (Aaronson et al., 2017; George et al., 2010; Lisanby et al., 2009; O'Reardon et al., 2007; Rush et al., 2005a; Sackeim et al., 2001c). With the same purposes of sample definition and outcome prediction, the ATHF was also applied in psychopharmacological studies (Blumberger et al., 2011; Hsu et al., 2016; Joel et al., 2014; Joo et al., 2005; Kocsis et al., 2008), and in relation to the adequacy of treatment surrounding sentinel events, such as suicide (Oquendo et al., 1999, 2002), or the adequacy of care in particular subgroups (Bacá-García et al., 2009; Dew et al., 2005), such as psychotic depression (Andreescu et al., 2007; Mulsant et al., 1997). The first version of the ATHF showed strong inter-rater reliability (Prudic et al., 1990; Sackeim et al., 1990), as did a subsequent version with computerized scoring (Oquendo et al., 2003). Summary scores on the ATHF have shown predictive validity in multiple prospective studies of treatment outcome and long-term course following a variety of types of pharmacological and brain stimulation interventions.

4. Antidepressant Treatment History Form: Short Form (ATHF-SF)

The last published revision of the ATHF criteria was in 2001 (Sackeim, 2001). In the interim there have been substantial changes in the psychopharmacological, brain stimulation, and psychotherapy interventions considered effective in the treatment of MDE. New medications and strategies are now in common practice, such as the use of atypical antipsychotic monotherapy in bipolar MDE or combination treatment with an antidepressant and an atypical antipsychotic medication for unipolar MDE. During this period, two neuromodulation treatments, TMS and VNS, were approved by the FDA with specific labelling for use in TRD. Many investigators using the ATHF made local modifications to account for this information.

The need for updating this instrument led to the creation of a workgroup tasked with producing a complete revision. The authors of this article constituted this workgroup, and are the authors of the new instrument, the Antidepressant Treatment History Form: Short Form (ATHF-SF). The group was chaired by Dr. Harold A. Sackeim, and the work of the group was partly supported by LivaNova, Inc, who intends to use the ATHF-SF in studies of VNS in TRD (see Disclosures). The original ATHF is now considered the long-form of the instrument (Sackeim, 2001).

In addition to this article, this workgroup produced four other documents: the ATHF-SF Instruction Manual, ATHF-SF Data Collection Forms for the Current Episode and as a Composite of Prior Episodes, and the ATHF-SF Scoring Checklist. The manual provides detailed instructions for collecting relevant data from a variety of sources and

applying the ATHF-SF trial-by-trial rating criteria. Many applications of the ATHF have only evaluated antidepressant trials in the current episode, with the view that information from earlier episodes is often unreliable. However, some applications of the ATHF pertained to lifetime exposure to antidepressants or address exposure to a particular treatment, such as ECT [e.g. (Aarons et al., 2017)]. Accordingly, the ATHF-SF has data collection forms dedicated to the current episode only or across prior episodes. The ATHF-SF Scoring Checklist provides a comprehensive list of all antidepressant treatments deemed effective in the treatment of MDEs based on review of the empirical evidence, treatment guidelines, regulatory approvals, and expert opinion, across the domains of pharmacotherapy, brain stimulation, and psychotherapy. Using a checklist format, notations are made as to whether or not the treatment was administered during the relevant time period and, if administered, whether the treatment exposure should be considered a “failed adequate trial”. The ATHF-SF presents explicit criteria to make this determination for every antidepressant treatment. These four documents can be freely downloaded at the end of this article as supplemental files. There are no restrictions on their use or dissemination.

The workgroup began by discussing fundamental issues in evaluating the adequacy of antidepressant treatments. These included identifying the domains of treatment that should be considered, the patient subgroups that required separate criteria (e.g., bipolar vs. unipolar MDE), how trial-by-trial ratings are made (e.g., dichotomous evaluation of adequacy vs. multi-level rating of trial potency), how antidepressant treatments should be grouped into classes, whether separate criteria should be offered for augmented or combination psychopharmacology trials (e.g., antidepressant plus lithium), and conventions for addressing trial dosage, duration, clinical benefit and adherence. The workgroup achieved consensus on these issues. Indeed, this article and the accompanying ATHF-SF documents were unanimously endorsed by this workgroup. After a draft ATHF-SF was created, the documents were shared with European experts in TRD, Drs. Koen Demyttenaere, Allan H. Young, and Thomas E. Schläpfer. Their comments prompted inclusion of some pharmaceutical agents not available in the United States, as well as modification of the psychotherapy criteria. The four ATHF-SF documents were finalized on December 5, 2018 as ATHF-SF Version 2018.1. The workgroup plans to update the ATHF-SF every 3–4 years.

This article reviews the key questions that must be addressed when evaluating the adequacy of antidepressant treatments and rating treatment resistance. In doing so, we detail the rationale behind the ATHF-SF.

5. Domains of treatment

Definitions of treatment resistance have often been restricted to psychopharmacological trials [e.g. (Thase and Rush, 1997)]. Some definitions include only ECT as a potentially adequate non-pharmacological treatment [e.g. (Fava, 2003; Fekadu et al., 2009)]. In recent years, brain stimulation interventions other than ECT have been found effective in the treatment of MDE. Indeed, TMS and VNS were each approved by the FDA specifically for different degrees of TRD. The ATHF-SF documents the administration of all brain stimulation interventions, and provides explicit criteria to assess the adequacy of three interventions with established efficacy, ECT, TMS, and VNS. Deep Brain Stimulation (DBS) (Dougherty et al., 2015; Holtzheimer et al., 2017), various forms of transcranial Electrical Stimulation (tES) (Brunoni et al., 2017; Inukai et al., 2016; Loo et al., 2018), and phototherapy (Mårtensson et al., 2015; Tuunainen et al., 2004) were determined at this time to have inconclusive evidence regarding efficacy in MDE, and, so while their use is documented, it is not rated for adequacy.

Only the staging model recently offered by Conway et al. (2017) includes insufficient benefit from an adequate trial of psychotherapy as contributing to the assessment of TRD. Neither the original ATHF nor the other instruments used to rate the adequacy of antidepressant trials

included psychotherapy as a potential source of treatment resistance. However, particular forms of psychotherapy have an evidence base that supports their efficacy in the treatment of MDE. These include: Behavior Therapy (BT) (Harley et al., 2008; Lynch et al., 2015), Cognitive-Behavioral Therapy (CBT) (Cristea et al., 2015; Feng et al., 2012; Gould et al., 2012; Gregory, 2010; Tolin, 2017), Interpersonal Therapy (IPT) (Cuijpers et al., 2016; Markowitz and Weissman, 2012; Weissman et al., 2014), Problem-Solving Therapy (PST) (Bell and D’Zurilla, 2009; Cuijpers et al., 2018; Townsend et al., 2001), and Short-term Psychodynamic Psychotherapy (STPP) (de Roten et al., 2017; Driessen et al., 2015, 2018). Furthermore, in recent years, there has been a burgeoning literature establishing the efficacy of evidence-based psychotherapies specifically in the treatment of TRD (Fonagy et al., 2015; Souza et al., 2016; Town et al., 2017; Trivedi et al., 2011; van Bronswijk et al., 2018). Thus, a significant change in the ATHF is provision of explicit criteria to rate the adequacy of specific forms of psychotherapy.

The workgroup considered and rejected inclusion of complementary, dietary, or naturopathic supplements as efficacious antidepressant treatments (e.g., S-adenosyl-L-methionine [SAM-e], St. John’s Wort, omega-3 fatty acids, folate, B-vitamins). Their exclusion was based on insufficient or inconsistent evidence of efficacy, especially as monotherapies, and concerns about consistency of dosing and bioavailability (American Psychiatric Association, 2010; Sarris et al., 2016). For example, the NIH National Center for Complementary and Integrative Health provides this bottom-line regarding use of St. John’s wort in depression: “St. John’s wort isn’t consistently effective for depression. Do not use it to replace conventional care or to postpone seeing your health care provider.”

6. Patient subgroups requiring distinct criteria

Other than the ATHF, instruments that assess the adequacy of antidepressant treatment have been restricted to nonpsychotic, unipolar MDE (Desseilles et al., 2011). This restriction was based on the evidence that differing pharmacological regimens are effective in the acute treatment of bipolar and unipolar MDE or nonpsychotic and psychotic MDE. For example, some medications have established efficacy in the acute treatment of bipolar MDE without similar information in the case of unipolar MDE (Bhagwagar and Goodwin, 2005; Bowden, 2002, 2003; Deshauer et al., 2005; Fountoulakis et al., 2017; Goodwin et al., 2016; Grunze et al., 2013; Muzina and Calabrese, 2003; Pacchiarotti et al., 2013). Consequently, in the ATHF-SF adequate trials can be achieved with lithium, specific anticonvulsants, or specific atypical antipsychotic medications in the acute treatment of bipolar, but not unipolar, MDE. In contrast, clozapine is treated differently, as criteria are given for adequate trials in either unipolar or bipolar MDE (Suppes and Rush, 1996; Suppes et al., 1999).

6.1. Unipolar vs. bipolar MDE

Another difference between bipolar and unipolar depression in the ATHF-SF is that augmentation strategies apply only to unipolar MDE. In bipolar, nonpsychotic MDE, all treatments are evaluated individually, regardless of their concurrent administration. Monotherapy trials with traditional antidepressant medications, lithium, specific anticonvulsants, and specific atypical antipsychotic medications can meet criteria for adequacy. In unipolar MDE, clozapine is the only antipsychotic that be an adequate monotherapy. In contrast, in unipolar MDE, the administration of augmentation trials is specifically evaluated. An adequate augmentation trial in unipolar patients can involve administration of adequate dose and duration of lithium, triiodothyronine (T3), or 5 specific atypical antipsychotics concurrently with adequate dose and duration of an antidepressant medication (e.g., nortriptyline plus lithium). The reason for this difference is that placebo-controlled, randomized trials have supported the efficacy of a variety of monotherapies in bipolar MDE, without comparable evidence

in unipolar MDE (Geddes and Miklowitz, 2013; Goodwin et al., 2016; Thase and Sachs, 2000). On the other hand, the evidence supporting the efficacy of lithium (Bauer et al., 2000; Fawcett, 2003; Januel et al., 2003; Nelson et al., 2014; Schule et al., 2009), T3 (Cooper-Kazaz et al., 2007; Joffe and Sokolov, 2000), or atypical antipsychotics (Gobbi et al., 2018; Nelson and Papakostas, 2009; Papakostas et al., 2007; Simons et al., 2017; Wang et al., 2015) in unipolar MDE derives mainly from trials where they were used in combination with or to augment antidepressant medications.

The role of traditional antidepressant medications in the acute treatment of bipolar MDE is controversial (Geddes and Miklowitz, 2013; Goodwin et al., 2016; Malhi et al., 2015; Pacchiarotti et al., 2013). Overall, the evidence for efficacy is relatively sparse and, at times, inconsistent (Sachs et al., 2007; Sidor and Macqueen, 2011; Vazquez et al., 2011, 2013). There are also the concerns that in some patients these medications may provoke mixed states or switches into mania (Baldessarini et al., 2013; Licht et al., 2008; Vazquez et al., 2011), or may destabilize the long-term course by promoting relapse or rapid-cycling (Altshuler et al., 1995; El-Mallakh et al., 2015). If a traditional antidepressant medication is used in bipolar MDE, most treatment guidelines recommend that a mood stabilizer be co-administered (Geddes and Miklowitz, 2013; Goodwin et al., 2016; Malhi et al., 2015; Pacchiarotti et al., 2013).

In the ATHF-SF, like the ATHF, no distinction is made between bipolar and unipolar MDE in evaluating monotherapies with traditional antidepressant medications. This approach was taken since meta-analyses have indicated that overall traditional antidepressants are more effective than placebo in bipolar MDE, and that the size of this effect is comparable to what is typically observed with unipolar MDE (Sidor and Macqueen, 2011; Vazquez et al., 2011, 2013). Furthermore, MDE with reversed vegetative features (i.e., atypical depression) is especially common in individuals with bipolar II MDE (Akiskal, 2005; Baldessarini et al., 2010; Blanco et al., 2012). In this subgroup, MAOIs, a specific class of traditional antidepressants, may be especially effective (Liebowitz et al., 1988; Quitkin et al., 1988).

Much of the concern about traditional antidepressants in bipolar MDE pertains their potential to produce mood instability, leading to the recommendations for combined treatment with a mood stabilizer. This destabilization is not universally observed or may only characterize a subgroup (Amsterdam et al., 2015). Regardless, the side effect potential of interventions does not impinge on ATHF-SF ratings of trial adequacy. Rather, interventions presumed to be potentially efficacious are evaluated in terms of dose, duration, adherence, and clinical outcome in order to determine resistance to a minimally adequate treatment regimen. Thus, ATHF-SF conventions for evaluating treatment resistance are not prescriptive regarding optimal care.

6.2. Psychotic vs. nonpsychotic MDE

Like the ATHF, the ATHF-SF has distinct criteria for pharmacological treatment of nonpsychotic and psychotic MDE. This approach derives from evidence that in psychotic MDE monotherapy with traditional antidepressant or antipsychotic medication is substantially less effective than combination treatment (Blumberger et al., 2011; Farahani and Correll, 2012; Glassman and Roose, 1981; Nelson et al., 1986; Spiker et al., 1985; Wijkstra et al., 2010, 2015). Thus, in the ATHF-SF, no trial of an antidepressant medication is considered adequate in the treatment of psychotic MDE unless that trial is combined with adequate dosage and duration of an antipsychotic medication. The minimal adequate dosage for the antipsychotic medication is 400 mg/d chlorpromazine (CPZ) equivalents based on research with first generation antipsychotics suggesting this cutoff (Nelson et al., 1986). The ATHF-SF Instruction Manual contains an appendix providing CPZ equivalencies for first and second-generation antipsychotic medications.

ECT is the only non-pharmacological intervention with substantial

evidence regarding potential differential efficacy in bipolar and unipolar MDE and nonpsychotic and psychotic MDE. Response and remission rates to ECT do not differ as a function of polarity, although bipolar patients as a group improve more quickly and require fewer treatments (Daly et al., 2001; Sackeim and Prudic, 2005; Sienaert et al., 2009). Both non-psychotic and psychotic MDE remit at high rates with ECT, and there is evidence that psychotic MDE may be especially ECT responsive (Flint and Rifat, 1998; Janicak et al., 1989; Petrides et al., 2001; Sobin et al., 1996; Solan et al., 1988). Thus, the ATHF-SF criteria for adequate trials of ECT do not differ for these subgroups. Due to the absence of evidence of differential efficacy, ATHF-SF criteria also do not differentiate among these subgroups in rating the adequacy of other brain stimulation interventions or psychotherapies.

7. Evaluation of treatment adequacy: dichotomy or continuum?

As indicated in Table 2, the original ATHF scored each antidepressant trial on a 5-point scale, with scores of “3” corresponding to an adequate trial and higher scores reflecting greater potency due to either increased dosage or blood level of a medication or use of specific augmentation strategies. This approach to scoring potency made use of the ATHF complex. Data collection involved tracking changes in dosages of medication and their specific duration to identify the highest dosage for the minimally acceptable period. The concurrent administration of medications needed to be tracked to identify trials requiring higher scores due to adequate augmentation regimens. The approach taken in the ATHF confounded higher potency scores due to high dosage with higher scores due to use of an adequate augmentation strategy.

Since the publication of the ATHF, alternative instruments have been proposed, such as the Antidepressant Treatment Record (ATR) (Carpenter et al., 2012; Dunner et al., 2014) and the ATRQ (Desseilles et al., 2011). Both instruments use a checklist format to identify minimally adequate treatment trials. Both instruments provide minimum dosages for antidepressant medications and minimum durations at that dose to identify adequate trials. Both instruments also collect information on clinical response to these trials, in order to identify “failed, adequate trials.” Both instruments make separate ratings of trials involving pharmacological augmentation or ECT.

Like the ATR and ATRQ, the ATHF-SF differs from the ATHF in that the scoring of each trial requires only the dichotomous determination of whether the trial was adequate, i.e., corresponding to a score of “3” on the ATHF. This change markedly simplifies scoring. All antidepressant interventions, pharmacological or otherwise, are rated independently, with notable exceptions made for (a) psychotic depression and (b) specific augmentation trials in unipolar depression, as discussed below. Other than these two exceptions, there is less need with the ATHF-SF to keep track whether medications were administered simultaneously or to track the dose changes of every medication. This greatly simplifies data collection and scoring. To be adequate, all pharmacological agents must be given for a minimum of 4 weeks at or above the stipulated minimum threshold dose or blood level. Once this is ascertained for a medication (or comparable criteria for brain stimulation and psychotherapy interventions), no further inquiry is necessary.

These changes were also prompted by the fact that few studies using the ATHF have reported potency scores [e.g. (Prudic et al., 1990; Sackeim et al., 1990)]. Almost all reports have focused on the total number of trials administered and the number of failed adequate trials (either in the current episode or lifetime). These summary scores are available with the ATHF-SF.

The ATHF-SF provides criteria to rate the adequacy of all interventions deemed effective treatments of MDE. These interventions are assessed in terms of whether they were administered and whether the intervention is considered a “failed adequate” trial. Two other types of intervention are also documented. Some interventions are borderline in terms of their evidence of efficacy. Promising treatments are

documented in the ATHF-SF that have not yet met the threshold for established efficacy, or where knowledge is lacking of minimal effective dose and duration. Examples include ketamine (Fava et al., 2018; Sanacora et al., 2017; Singh et al., 2016; Wilkinson et al., 2018) and pramipexole (Dell'Osso and Ketter, 2013; Fawcett et al., 2016; Gauthier et al., 2017; Lattanzi et al., 2002). In contrast, reboxetine is included in this grouping since information subsequent to its regulatory approval in Europe has created doubt regarding its efficacy. For brain stimulation interventions, this grouping includes various forms of tES, DBS, and light therapy. The administration of any of these specific interventions is noted (at any dose or duration), but they cannot constitute adequate trials. The third grouping involves classes of medication often used adjunctively in MDE treatment but thought to have minimal efficacy on core MDE symptoms. These classes include benzodiazepines, stimulants, specific anticonvulsants and antipsychotics in bipolar MDE, and specific antipsychotics in unipolar MDE. Notation is made if any member of the class was administered during the rating period, regardless of whether multiple members of the class were prescribed.

The structure of the ATHF-SF distinguishes among treatment domains (pharmacotherapy, brain stimulation, psychotherapy), classes of treatment, and specific interventions within a class. For pharmacological treatment, classes are defined following traditional distinctions regarding presumed pharmacological mechanisms (e.g., SSRI, SNRI, TCA, anticonvulsants, etc.). Each brain stimulation or psychotherapy intervention is considered a separate class. Thus, the ATHF-SF can provide summary scores for the number of antidepressant trials attempted and the number of “failed adequate” trials within the three domains, within specific treatment classes, and across all interventions.

8. Combination and augmentation strategies

As noted, due to the evidence that the combination of antipsychotic and antidepressant medication is more effective than either alone in the treatment of psychotic MDE (Blumberger et al., 2011; Farahani and Correll, 2012; Glassman and Roose, 1981; Nelson et al., 1986; Spiker et al., 1985; Wijkstra et al., 2010, 2015), the ATHF-SF requires such combination treatment for an adequate pharmacological trial in this subgroup.

In unipolar MDE, there is also a substantial literature on the use of particular augmentation strategies following lack of response with a traditional antidepressant medication. Randomized placebo-controlled trials have shown that adding lithium (Bauer et al., 2000; Fawcett, 2003; Januel et al., 2003; Nelson et al., 2014; Schule et al., 2009), T3 (Bauer et al., 2000; Fawcett, 2003; Januel et al., 2003; Nelson et al., 2014; Schule et al., 2009), or specific atypical antipsychotic medications (Gobbi et al., 2018; Nelson and Papakostas, 2009; Papakostas et al., 2007; Simons et al., 2017; Wang et al., 2015) are effective augmentation strategies (Thase, 2009; Thase and Rush, 1997; Zhou et al., 2015). The workgroup felt that the information conveyed from failure to benefit from an adequate augmentation strategy in unipolar MDE was different from failing adequate monotherapy trials of the constituents. In contrast, augmentation strategies are less established in bipolar MDE. Instead, in this subgroup there is evidence that specific agents often used in augmentation strategies, such as lithium or particular anticonvulsants or atypical antipsychotics are effective as monotherapies (Geddes and Miklowitz, 2013; Goodwin et al., 2016; Thase and Sachs, 2000). Consequently, in nonpsychotic bipolar MDE all treatments are evaluated individually regardless of their concurrent use, as if they were administered as monotherapies. This is also the case in nonpsychotic, unipolar MDE, except for the concurrent administration of augmentation strategies with lithium, T3, or specific atypical antipsychotics. While augmentation trials imply prior lack of benefit with the antidepressant being “augmented”, in the ATHF-SF any period of failed adequate concurrent treatment is considered when evaluating “augmentation” trials.

9. Dosage, duration, adherence, and clinical outcome

It is generally agreed that any definition of a “failed adequate” trial must operationalize (a) the minimum dose of an intervention considered effective; (b) the minimum duration of treatment at or above that dosage for the trial to be considered adequate; (c) the extent to which nonadherence with the regimen disqualifies a trial; and (4) the extent of clinical improvement that justifies characterizing the trial as unsuccessful or “failed” (Berlim and Turecki, 2007a; Sackeim, 2001). In reviewing 47 RCTs in TRD, Berlin and Turecki (2007b) found marked variability in the conventions used to define each component.

9.1. Dosage and duration

The ATHF, ATR, and ATRQ provide criteria for the minimum effective dose and duration for pharmacological treatments to be considered adequate. These criteria largely reflect the minimum dose for which there is evidence from RCTs demonstrating antidepressant efficacy. The ATHF-SF follows this principle. In addition, for some medications blood level information takes precedence over oral dosage (e.g., nortriptyline, lithium), and minimal values are given for adequate blood levels.

There is also considerable variability in the definitions used for adequate duration of pharmacotherapy. A minimum of four weeks has been the most commonly used cutoff, but TRD studies have also required six or eight weeks for trials to be considered adequate (Berlin and Turecki, 2007b). The ATHF (Sackeim, 2001) and ATR (Carpenter et al., 2012; Dunner et al., 2014) use a four-week minimum cutoff, while the ATRQ (Desseilles et al., 2011) requires 6 weeks. Given uncertainty about the optimal duration cutoff, the ATRQ also documents whether the minimal dosage was given for at least 10 weeks.

Other than ketamine (Sanacora et al., 2017), there is little evidence that antidepressant regimens differ in their speed of improvement (Gelenberg and Chesen, 2000; Machado-Vieira et al., 2010). Consequently, the workgroup determined that use of the same treatment duration criterion across all pharmacological interventions was justified and would greatly simplify data collection and scoring. While the duration of acute phase treatment in antidepressant RCTs has increased in recent decades (Sackeim et al., 2006), this does not bear directly on the question of what minimally adequate trial duration is informative of treatment resistance. There is substantial evidence that early clinical improvement with antidepressant pharmacotherapy has positive predictive value regarding ultimate response or remission, and that early lack of symptomatic improvement has negative predictive value (Leuchter et al., 2009; Nierenberg et al., 1995; Papakostas et al., 2006; Sackeim et al., 2006; Szegedi et al., 2009).

The ATHF-SF maintains the convention adopted in the ATHF and ATR requiring a four-week minimum duration to declare a trial as adequate. While this choice was arbitrary, it had the advantage of recognizing that total duration of exposure to a medication is often longer due to upward titration of dose at treatment outset. More critically, it was thought that failure to show substantial improvement after a minimum four-week trial was informative of likely resistance to that medication. Use of this cutoff also had the advantage of continuity with earlier studies using the ATHF and ATR.

Even though the original ATHF only required a minimum four-week duration of medication exposure, in many studies the total number of medication trials administered was two-to-four times more common than the total number of failed adequate medication trials (George et al., 2010; Lisanby et al., 2009; Sackeim et al., 2001b, 2009). Low rates of adequate antidepressant treatment (i.e., below minimum thresholds for dose and/or duration) have been repeatedly documented, since the earliest assessment of treatment adequacy in MDE (Keller et al., 1982, 1986) and until the present (Andrescu et al., 2007; Fife et al., 2018; Kocsis et al., 2008). For example, using the ATHF, Kocsis et al. (2008) found that only 33% of 80 patients with chronic

forms of MDE had ever received an adequate antidepressant medication trial. The minimum treatment duration for pharmacotherapy is perhaps the ATHF-SF criterion most likely to be modified for particular research needs. It should be recognized that lengthening this criterion (or increasing medication dose) may purify TRD samples by reducing the false positive rate, but will also increase false negatives and reduce the incidence of TRD.

The adequacy of pharmacological treatment can be characterized in terms of oral dosage (or blood levels) and treatment duration. In contrast, multiple dimensions potentially impact on the adequacy of brain stimulation and psychotherapy interventions. For example, the efficacy and side effects of ECT are contingent on electrode placement and electrical dosage relative to seizure threshold, electrical waveform, and other technical factors (Sackeim et al., 1993, 2000, 2008; Semkowska et al., 2016). TMS can be characterized in terms of site of stimulation and method of ascertainment, dosing relative to motor threshold, stimulation parameters and pulse number, coil geometry, frequency of treatments, treatment number, etc. (Blumberger et al., 2018; George et al., 2010; Levkovitz et al., 2015; O'Reardon et al., 2007). Completely different dimensions apply to psychotherapies, including session duration, frequency, and number, individual, couple, family, or group format, manual-guided, therapist experience, theoretical orientation, etc. (Garland et al., 2010). The workgroup recognized that patients rarely can report the technical details regarding previous brain stimulation or psychotherapy interventions, and this information is also often missing from medical records.

In this context, the workgroup adopted a minimalist approach to evaluating trial adequacy, similar in concept to the approach taken with medications. Brain stimulation and psychotherapy interventions all require a minimum number of “sessions” or treatments within a prescribed timeframe. Specifically, an adequate trial of ECT corresponds to a course of at least eight treatments given within a 5-week period (Kellner et al., 2016; Sackeim et al., 2009). An adequate trial of TMS involves at least 20 sessions within a 6-week period of either fast (≥ 5 Hz) left frontal or slow (≤ 1 Hz) right frontal stimulation (Carpenter et al., 2012; Chen et al., 2013; Gaynes et al., 2014; Liu et al., 2014). Given the evidence for an especially slow onset of benefit, an adequate trial of VNS corresponds to implantation and stimulation for a year or more, with the current set at 0.75 mA or higher (Aaronson et al., 2017; Rush et al., 2005a, 2005b; Sackeim et al., 2001b, 2007).

Five forms of evidence-based psychotherapy are identified in the ATHF-SF as potentially adequate treatments: Behavior Therapy (BT), Cognitive-Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Problem-Solving Therapy (PST), and Short-term Psychodynamic Psychotherapy (STPP). To be considered adequate, patients must participate in at least 12 sessions within a 15-week period. Thus, the same criteria for minimum intensity of treatment apply to all psychotherapy interventions. Treatment may be given in an individual, couple, family, or group format as long as the primary orientation reflects one of the evidence-based psychotherapies and the primary target of treatment is the patient's depression.

9.2. Adherence

Studies of TRD rarely describe compliance or adherence criteria when evaluating antidepressant resistance (Berlim and Turecki, 2007b). However, failure to receive a therapy due to nonadherence (for whatever reason) contradicts evaluating the treatment as adequate. The ATHF-SF explicitly states that to rate a trial as adequate, “there should not be evidence that the patient was substantially non-adherent with the treatment regimen.” For pharmacotherapy, substantial non-adherence would involve evidence (including self-report) that 25% or more of the prescribed medication doses were not administered during the relevant period. For psychotherapy, evidence of non-adherence might include refusal to engage in sessions, lack of completion of assignments, etc. Non-adherence is rarely an issue for brain stimulation

interventions as their administration does not typically require active patient participation. Explicit evidence of non-adherence is needed to exclude a trial from being rated as adequate.

9.3. Treatment outcome

When used solely to evaluate the adequacy of care, treatment therapeutic outcome is not a relevant consideration. The ATHF has been used to characterize the intensity or adequacy of pharmacological treatment in a variety of subgroups (Andreescu et al., 2007; Kocsis et al., 2008; Mulsant et al., 1997; Oquendo et al., 1999, 2002). However, the concept of treatment resistance requires there be insufficient benefit from an adequate trial. Studies of TRD have varied markedly in the criteria used to document that previous trials were unsuccessful. Criteria have ranged from failing to achieve complete remission to failing to manifest a 30% reduction in symptom severity (Berlim and Turecki, 2007b). This diversity reflects the tension between the consensus that the goal of antidepressant treatment should be symptomatic remission, especially since the extent of residual symptoms may predict relapse, and the clinical reality that for some patients partial improvement may be particularly meaningful in the context of a chronic and treatment-resistant course.

In line with the majority of studies in this area (Berlim and Turecki, 2007b), the ATHF-SF takes a middle course between these positions. To be rated as a “failed, adequate” trial, patients should not have shown marked clinical improvement or remission at the end of the treatment period. The ATHF-SF uses a modified Clinical Global Impression — Improvement Scale (CGI-I) (Guy, 1976), where scores of “1” and “2” correspond to “very much improved” and “much improved”. Any trial receiving a score of 1 or 2 is disqualified as a “failed, adequate” trial. Scores of 3 through 7 correspond to the traditional CGI-I anchors ranging from “minimally improved” to “very much worse”. Any score in this range would constitute an unsuccessful trial. This demarcation also corresponds to the distinction between “response” and “non-response” (Frank et al., 1991; Rush et al., 2006a), such that any patient showing a 50% or greater improvement in symptom severity should not be considered as having a failed trial. The ATHF-SF adds another anchor in scoring the CGI-I for each trial. Scores of “8” correspond to a trial in which the patient was much or very much improved but then relapsed on the same regimen. Such instances of antidepressant tachyphylaxis often indicate the onset on a new MDE (Targum, 2014). The ATHF-SF Instruction Manual makes specific recommendations on how to evaluate instances of loss of benefit for previously effective antidepressant treatment.

10. Sources of data

The reliability and validity of the information submitted to ATHF-SF scoring are enhanced by comprehensive attempts to obtain information from diverse sources. Pharmacy records may be especially useful in documenting prescribed oral dosage and the duration of treatment. Patient and family member interviews may be key to evaluating adherence and clinical outcome. Consultation with past providers may be needed to verify clinical outcome and the reason for trial discontinuation. Reviewing medical records may be necessary to document blood levels. While obtaining comprehensive information on antidepressant trial details can be onerous and time consuming, such information is necessary for accurate evaluation of treatment adequacy and resistance.

11. Conclusions

There is considerable diversity in the definitions and metrics used to categorize and quantify antidepressant treatment resistance. However, all approaches to this problem require that patients experience insufficient benefit during one or more adequate antidepressant treatment trials, and the identification of “failed, adequate trials” is at the

core of methods for assessing TRD. The evaluation of antidepressant treatment trials in term of their adequacy, adherence, and clinical outcome raises a host of complex issues, and the empirical evidence often offers only limited guidance. The field has not achieved consensus on many of these topics. Nonetheless, the reliable and valid identification of TRD is fundamental to treatment planning, research, and public policy. We have summarized the rationale behind the ATHF-SF and described how it addresses each of the key issues.

Declaration of interest

Dr. Harold A. Sackeim has served as a consultant and/or received research support from the brain stimulation companies: Brainsway Ltd., Cervel Neurotech Inc./NeoStim Inc., Cyberonics Inc., LivaNova PLC, Magstim Ltd., MECTA Corp., NeoSync Inc., Neuronetics Inc., and NeuroPace Inc. and from the pharmaceutical companies: Cambridge Neuroscience Inc., Eli Lilly & Co., Forest Laboratories, Hoffman-La Roche AG, Interneuron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., Warner-Lambert, Inc., and Wyeth-Ayerst, Inc. He holds non-remunerative patents with the MECTA Corporation for Focal Electrically-Administered Seizure Therapy (FEAST) and for Titration in the Current Domain. He is the originator of Magnetic Seizure Therapy. He has received royalties from Oxford University Press and Elsevier Inc. His effort in chairing this revision of the ATHF and drafting the ATHF-SF documents was partially supported by LivaNova PLC. LivaNova PLC partly supported the deliberations that resulted in the ATHF-SF with the aim of using this instrument in future research on VNS in TRD. However, neither LivaNova PLC, or any other commercial entity, had any substantive influence on the design or content of the ATHF-SF.

Dr. Scott T. Aaronson reports no conflicts of interest directly relating to this work. He does report a number of other relationships with commercial entities. He serves as a consultant to LivaNova PLC, Neuronetics Inc., Janssen Pharmaceuticals Inc., and Genomind. He has received research support from Neuronetics Inc. He has been paid speaker honoraria by Sunovion Pharmaceuticals Inc. and Neurocrine Biosciences Inc.

Dr. Mark Bunker reports no conflicts of interest directly relating to this work. He is a consultant to LivaNova, PLC.

Dr. Mark Demitrack reports no conflicts of interest directly relating to this work. He serves as a consultant and has stock ownership in Neuronetics, Inc. He is an employee of Axovant Sciences, Inc.

Dr. Charles R. Conway reports no conflicts of interest directly relating to this work. He has received research support from Bristol-Myers Squibb Co., Stanley Medical Research Institute, National Institute of Mental Health, NeoSync Inc., Cyberonics Inc., Taylor Family Institute for Innovative Psychiatric Research, August Busch IV Foundation, and Barnes-Jewish Hospital Foundation. He previously served as a speaker for Bristol-Myers Squibb Co. and Otsuka Pharmaceuticals Co. He currently serves as a paid consultant to LivaNova PLC in designing studies involving VNS.

Dr. Mark S. George reports no conflicts of interest directly relating to this work. He has no equity ownership in any device or pharmaceutical company. He does occasionally consult with industry, although he has not accepted consulting fees from anyone who manufactures a TMS device, because of his role in NIH and DOD/VA studies evaluating this technology. His total industry related compensation per year is less than 10% of his total university salary. In the past two years, his industry involvement has included Brainsonix Corp. (unpaid consultant), Brainsway Ltd. (unpaid consultant, research grant, donated equipment), Cervel Neurotech Inc./NeoStim Inc. (unpaid consultant, research grant), LivaNova PLC (consultant), MECTA Corp. (unpaid consultant, research grant), Microtransponder Inc. (DSMB member), Neuronetics Inc. (unpaid consultant, research grant, donated equipment), NeoSync (unpaid consultant, research grant), Nerve (unpaid consultant), Pure Tech Health Ventures (consultant).

Dr. Joan Prudic reports no conflicts of interest.

Dr. Michael E. Thase reports no conflicts of interest directly relating to this work. He does report a number of other relationships with commercial entities. During the past 3 years, he has been an advisory/consultant to Acadia, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Johnson & Johnson (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Merck, Mocksha8, Nestlé (PamLab), Neuronetics, Novartis, Otsuka, Pfizer, Shire, Sunovion, and Takeda. In addition to the National Institute of Mental Health, he received grant support from Acadia, the Agency for Healthcare Research and Quality, Alkermes, Assurex, Avanir, Forest Pharmaceuticals, Johnson & Johnson, Otsuka Pharmaceuticals, and Takeda. Dr. Thase received royalties from the American Psychiatric Press, Guilford Publications, Herald House and W.W. Norton & Company, Inc. Dr. Thase's spouse, Dr. Diane Sloan, works for Peloton Advantage, which did business with Pfizer and AstraZeneca.

Dr. A. John Rush has served as a consultant to Akili Inc., American Psychiatric Association, Brain Resource Ltd., Compass Inc., Curbstone Consultant LLC., Cyberonics Inc., Eli Lilly, Emmes Corp., Holmusk, LivaNova PLC, National Institute of Drug Abuse, Santium Inc., Sunovion, Taj Medical, Takeda USA. He has received speaking fees from LivaNova and royalties from Guilford Publications and the University of Texas Southwestern Medical Center, Dallas, Tx. (for the Inventory of Depressive Symptoms and its derivatives). He is a named co-inventor on U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS and on U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. His effort in assisting in the drafting of this revision of the ATHF and associated ATHF-SF documents was partially supported by LivaNova PLC.

Acknowledgements

We thank Professors Koen Demyttenaere, Allan H. Young and Thomas E. Schlöpfer for their comments on the ATHF-SF. Their comments prompted inclusion of some pharmaceutical agents not available in the United States, as well as modification of the psychotherapy criteria. We also thank Ms. Amy Keith and Ms. Renske De Zwaef of LivaNova PLC for organizational assistance with the deliberations of the co-authors that resulted in the ATHF-SF 2018 Version 1.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jpsychires.2019.03.021>.

References

- Aaronson, S.T., Sears, P., Ruvuna, F., Bunker, M., Conway, C.R., Dougherty, D.D., Reimherr, F.W., Schwartz, T.L., Zajecka, J.M., 2017. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. *Am. J. Psychiatry* 174 (7), 640–648.
- Akiskal, H.S., 2005. The dark side of bipolarity: detecting bipolar depression in its pleomorphic expressions. *J. Affect. Disord.* 84 (2–3), 107–115.
- Altshuler, L.L., Post, R.M., Leverich, G.S., Mikalaukas, K., Rosoff, A., Ackerman, L., 1995. Antidepressant-induced mania and cycle acceleration: a controversy revisited. *Am. J. Psychiatr.* 152 (8), 1130–1138.
- American Psychiatric Association, 2010. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third ed. American Psychiatric Publishing, Inc, Washington, D.C.
- Amos, T.B., Tandon, N., Lefebvre, P., Pilon, D., Kamstra, R.L., Pivneva, I., Greenberg, P.E., 2018. Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database. *J. Clin. Psychiatr.* 79 (2).
- Amsterdam, J.D., Lorenzo-Luaces, L., Soeller, I., Li, S.Q., Mao, J.J., DeRubeis, R.J., 2015. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. *J. Affect. Disord.* 185, 31–37.
- Andreescu, C., Mulsant, B.H., Peasley-Miklus, C., Rothschild, A.J., Flint, A.J., Heo, M.,

- Caswell, M., Whyte, E.M., Meyers, B.S., Group, S.-P.S., 2007. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. *J. Clin. Psychiatr.* 68 (2), 194–200.
- Baca-Garcia, E., Sher, L., Perez-Rodriguez, M.M., Burke, A.K., Sullivan, G.M., Grunebaum, M.F., Stanley, B.H., Mann, J.J., Quenzo, M.A., 2009. Treatment of depressed bipolar patients with alcohol use disorders: plenty of room for improvement. *J. Affect. Disord.* 115 (1–2), 262–268.
- Baldessarini, R.J., Faedda, G.L., Offidani, E., Vazquez, G.H., Marangoni, C., Serra, G., Tondo, L., 2013. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. *J. Affect. Disord.* 148 (1), 129–135.
- Baldessarini, R.J., Vieta, E., Calabrese, J.R., Tohen, M., Bowden, C.L., 2010. Bipolar depression: overview and commentary. *Harv. Rev. Psychiatr.* 18 (3), 143–157.
- Banankhah, S.K., Friedmann, E., Thomas, S., 2015. Effective treatment of depression improves post-myocardial infarction survival. *World J. Cardiol.* 7 (4), 215–223.
- Bauer, M., Bschor, T., Kunz, D., Berghofer, A., Strohle, A., Muller-Oerlinghausen, B., 2000. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. *Am. J. Psychiatr.* 157 (9), 1429–1435.
- Bell, A.C., D'Zurilla, T.J., 2009. Problem-solving therapy for depression: a meta-analysis. *Clin. Psychol. Rev.* 29 (4), 348–353.
- Berlim, M.T., Turecki, G., 2007a. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. *Can. J. Psychiatr.* 52 (1), 46–54.
- Berlim, M.T., Turecki, G., 2007b. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. *Eur. Neuropsychopharmacol.* 17 (11), 696–707.
- Bhagwagar, Z., Goodwin, G.M., 2005. Lamotrigine in the treatment of bipolar disorder. *Expert Opin. Pharmacother.* 6 (8), 1401–1408.
- Blanco, C., Vesga-Lopez, O., Stewart, J.W., Liu, S.M., Grant, B.F., Hasin, D.S., 2012. Epidemiology of major depression with atypical features: results from the national epidemiologic survey on alcohol and related conditions (NESARC). *J. Clin. Psychiatr.* 73 (2), 224–232.
- Blumberger, D.M., Mulsant, B.H., Emeremni, C., Houck, P., Andreescu, C., Mazumdar, S., Whyte, E., Rothschild, A.J., Flint, A.J., Meyers, B.S., 2011. Impact of prior psychotherapy on remission of psychotic depression in a randomized controlled trial. *J. Psychiatr. Res.* 45 (7), 896–901.
- Blumberger, D.M., Vila-Rodriguez, F., Thorpe, K.E., Feffer, K., Noda, Y., Giacobbe, P., Knyahnytska, Y., Kennedy, S.H., Lam, R.W., Daskalakis, Z.J., Downar, J., 2018. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. *Lancet* 391 (10131), 1683–1692.
- Bowden, C.L., 2002. Lamotrigine in the treatment of bipolar disorder. *Expert Opin. Pharmacother.* 3 (10), 1513–1519.
- Bowden, C.L., 2003. Acute and maintenance treatment with mood stabilizers. *Int. J. Neuropsychopharmacol.* 6 (3), 269–275.
- Brunoni, A.R., Moffa, A.H., Sampaio-Junior, B., Borriore, L., Moreno, M.L., Fernandes, R.A., Veronezi, B.P., Nogueira, B.S., Aparicio, L.V.M., Razza, L.B., Chamorro, R., Tort, L.C., Fraguas, R., Lotufo, P.A., Gattaz, W.F., Fregni, F., Bensenor, I.M., Investigators, E.-T., 2017. Trial of electrical direct-current therapy versus escitalopram for depression. *N. Engl. J. Med.* 376 (26), 2523–2533.
- Carpenter, L.L., Janicak, P.G., Aaronson, S.T., Boyadjis, T., Brock, D.G., Cook, I.A., Dunner, D.L., Lanocha, K., Solvason, H.B., Demitrack, M.A., 2012. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. *Depress. Anxiety* 29 (7), 587–596.
- Center for Drug Evaluation and Research (CDER), 2018. Major Depressive Disorder: Developing Drugs for Treatment Guidance for Industry. <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM611259.pdf>, Accessed date: 1 October 2018 2018.
- Cepeda, M.S., Reys, J., Fife, D., Blacketer, C., Stang, P., Ryan, P., 2018. Finding treatment-resistant depression in real-world data: how a data-driven approach compares with expert-based heuristics. *Depress. Anxiety* 35 (3), 220–228.
- Chen, J., Zhou, C., Wu, B., Wang, Y., Li, Q., Wei, Y., Yang, D., Mu, J., Zhu, D., Zou, D., Xie, P., 2013. Left versus right repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomised controlled trials. *Psychiatr. Res.* 210 (3), 1260–1264.
- Conway, C.R., George, M.S., Sackeim, H.A., 2017. Towards an evidence-based, operational definition of treatment-resistant depression: when enough is enough. *JAMA Psychiatr.* 74 (1), 9–10.
- Cooper-Kazaz, R., Apter, J.T., Cohen, R., Karagichev, L., Muhammed-Moussa, S., Grupper, D., Drori, T., Newman, M.E., Sackeim, H.A., Glaser, B., Lerer, B., 2007. Combined treatment with sertraline and lithium in major depression: a randomized, double-blind, placebo-controlled trial. *Arch. Gen. Psychiatr.* 64 (6), 679–688.
- Cristea, I.A., Huibers, M.J., David, D., Hollon, S.D., Andersson, G., Cuijpers, P., 2015. The effects of cognitive behavior therapy for adult depression on dysfunctional thinking: a meta-analysis. *Clin. Psychol. Rev.* 42, 62–71.
- Cuijpers, P., de Wit, L., Kleiboer, A., Karyotaki, E., Ebert, D.D., 2018. Problem-solving therapy for adult depression: an updated meta-analysis. *Eur. Psychiatr.* 48, 27–37.
- Cuijpers, P., Donker, T., Weissman, M.M., Ravitz, P., Cristea, I.A., 2016. Interpersonal psychotherapy for mental health problems: a comprehensive meta-analysis. *Am. J. Psychiatr.* 173 (7), 680–687.
- Daly, J.J., Prudic, J., Devanand, D.P., Nobler, M.S., Lisanby, S.H., Peyser, S., Roose, S.P., Sackeim, H.A., 2001. ECT in bipolar and unipolar depression: differences in speed of response. *Bipolar Disord.* 3 (2), 95–104.
- de Roten, Y., Ambresin, G., Herrera, F., Fassassi, S., Fournier, N., Preisig, M., Despland, J.N., 2017. Efficacy of an adjunctive brief psychodynamic psychotherapy to usual inpatient treatment of depression: results of a randomized controlled trial. *J. Affect. Disord.* 209, 105–113.
- Dell'Osso, B., Ketter, T.A., 2013. Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data. *Int. Clin. Psychopharmacol.* 28 (6), 297–304.
- Demyttenaere, K., Van Duppen, Z., 2019. The impact of (the concept of) treatment-resistant depression: an opinion review. *Int. J. Neuropsychopharmacol.* 22 (2), 85–92.
- Deshauer, D., Fergusson, D., Duffy, A., Albuquerque, J., Grof, P., 2005. Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect. *Bipolar Disord.* 7 (4), 382–387.
- Desseilles, M., Witte, J., Chang, T.E., Iovieno, N., Dording, C.M., Ashih, H., Nyer, M., Freeman, M.P., Fava, M., Mischoulon, D., 2011. Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire. *J. Clin. Psychiatr.* 72 (8), 1152–1154.
- Dew, R.E., Kramer, S.L., McCall, W.V., 2005. Adequacy of antidepressant treatment by psychiatric residents: the antidepressant treatment history form as a possible assessment tool. *Acad. Psychiatr.* 29 (3), 283–288.
- Dombrovski, A.Y., Mulsant, B.H., Haskett, R.F., Prudic, J., Begley, A.E., Sackeim, H.A., 2005. Predictors of remission after electroconvulsive therapy in unipolar major depression. *J. Clin. Psychiatr.* 66 (8), 1043–1049.
- Dougherty, D.D., Rezaei, A.R., Carpenter, L.L., Howland, R.H., Bhati, M.T., O'Reardon, J.P., Eskandar, E.N., Baltuch, G.H., Machado, A.D., Kondziolka, D., Cusin, C., Evans, K.C., Price, L.H., Jacobs, K., Pandya, M., Denko, T., Tyrka, A.R., Brejle, T., Deckersbach, T., Kubu, C., Malone Jr., D.A., 2015. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. *Biol. Psychiatr.* 78 (4), 240–248.
- Drissen, E., Abbass, A.A., Barber, J.P., Connolly Gibbons, M.B., Dekker, J.J.M., Fokkema, M., Fonagy, P., Hollon, S.D., Jansma, E.P., de Maat, S.C.M., Town, J.M., Twisk, J.W.R., Van, H.L., Weitz, E., Cuijpers, P., 2018. Which patients benefit specifically from short-term psychodynamic psychotherapy (STPP) for depression? Study protocol of a systematic review and meta-analysis of individual participant data. *BMJ open* 8 (2), e018900.
- Drissen, E., Hegelmaier, L.M., Abbass, A.A., Barber, J.P., Dekker, J.J., Van, H.L., Jansma, E.P., Cuijpers, P., 2015. The efficacy of short-term psychodynamic psychotherapy for depression: a meta-analysis update. *Clin. Psychol. Rev.* 42, 1–15.
- Dunner, D.L., Aaronson, S.T., Sackeim, H.A., Janicak, P.G., Carpenter, L.L., Boyadjis, T., Brock, D.G., Bonneh-Barkay, D., Cook, I.A., Lanocha, K., Solvason, H.B., Demitrack, M.A., 2014. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. *J. Clin. Psychiatr.* 75 (12), 1394–1401.
- El-Mallakh, R.S., Vohringer, P.A., Ostacher, M.M., Baldassano, C.F., Holtzman, N.S., Whitham, E.A., Thommi, S.B., Goodwin, F.K., Ghaemi, S.N., 2015. Antidepressants worsen rapid-cycling course in bipolar depression: a STEP-BD randomized clinical trial. *J. Affect. Disord.* 184, 318–321.
- European Medicines Agency, 2013. Guideline on Clinical Investigation of Medicinal Products in the Treatment of Depression. European Medicines Agency, London.
- Farahani, A., Correll, C.U., 2012. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. *J. Clin. Psychiatr.* 73 (4), 486–496.
- Fava, M., 2003. Diagnosis and definition of treatment-resistant depression. *Biol. Psychiatry* 53 (8), 649–659.
- Fava, M., Freeman, M.P., Flynn, M., Judge, H., Hoepfner, B.B., Cusin, C., Ionescu, D.F., Mathew, S.J., Chang, L.C., Iosifescu, D.V., Murrough, J., Sebattista, C., Schatzberg, A.F., Trivedi, M.H., Jha, M.K., Sanacora, G., Wilkinson, S.T., Papakostas, G.I., 2018. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). *Mol. Psychiatr.* (in press).
- Fawcett, J., Rush, A.J., Vukelich, J., Diaz, S.H., Dunklee, L., Romo, P., Yarns, B.C., Escalona, R., 2016. Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression. *Am. J. Psychiatr.* 173 (2), 107–111.
- Fawcett, J.A., 2003. Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. *J. Clin. Psychiatr.* 64 (Suppl. 5), 32–37.
- Fekadu, A., Wooderson, S.C., Markopoulou, K., Cleare, A.J., 2009. The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. *J. Clin. Psychiatr.* 70 (7), 952–957.
- Feng, C.Y., Chu, H., Chen, C.H., Chang, Y.S., Chen, T.H., Chou, Y.H., Chang, Y.C., Chou, K.R., 2012. The effect of cognitive behavioral group therapy for depression: a meta-analysis 2000–2010. *Worldviews Evidence-Based Nurs.* 9 (1), 2–17.
- Fife, D., Blacketer, C., Reys, J.M., Ryan, P., 2018. Database studies of treatment-resistant depression should take account of adequate dosing. *Prim Care Companion CNS Disord* 20 (4).
- Fife, D., Feng, Y., Wang, M.Y., Chang, C.J., Liu, C.Y., Juang, H.T., Furnback, W., Singh, J., Wang, B., 2017. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. *Psychiatr. Res.* 252, 277–283.
- Flint, A.J., Rifat, S.L., 1998. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. *Int. J. Geriatr. Psychiatr.* 13 (1), 23–28.
- Fonagy, P., Rost, F., Carlyle, J.A., McPherson, S., Thomas, R., Pasco Fearon, R.M., Goldberg, D., Taylor, D., 2015. Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS). *World Psychiatr.* 14 (3), 312–321.
- Fountoulakis, K.N., Grunze, H., Vieta, E., Young, A., Yatham, L., Blier, P., Kasper, S., Moeller, H.J., 2017. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. *Int. J. Neuropsychopharmacol.* 20 (2), 180–195.

- Frank, E., Prien, R.F., Jarrett, R.B., Keller, M.B., Kupfer, D.J., Lavori, P.W., Rush, A.J., Weissman, M.M., 1991. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. *Arch. Gen. Psychiatr.* 48 (9), 851–855.
- Garland, A.F., Hurlburt, M.S., Brookman-Frazee, L., Taylor, R.M., Accurso, E.C., 2010. Methodological challenges of characterizing usual care psychotherapeutic practice. *Adm. Policy Ment. Health* 37 (3), 208–220.
- Gauthier, C., Souaiby, L., Advénier-Iakovlev, E., Gaillard, R., 2017. Pramipexole and electroconvulsive therapy in treatment-resistant depression. *Clin. Neuropharmacol.* 40 (6), 264–267.
- Gaynes, B., Asher, G., Gartlehner, G., Hoffman, V., Green, J., Boland, J., Lux, L., Weber, R., Randolph, C., Bann, C., Coker-Schwimmer, E., Viswanathan, M., Lohr, K., 2018. Definition of Treatment-Resistant Depression in the Medicare Population. , Technology Assessment Program. Project ID: PSYT0816. (Prepared by RTI-UNC Evidence-Based Practice Center under Contract No. HHS290201500011, HHS29032006T). Agency for Healthcare Research and Quality, Rockville, MD. <http://www.ahrq.gov/clinic/epcix.htm>.
- Gaynes, B.N., Lloyd, S.W., Lux, L., Gartlehner, G., Hansen, R.A., Brode, S., Jonas, D.E., Swinson Evans, T., Viswanathan, M., Lohr, K.N., 2014. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. *J. Clin. Psychiatry* 75 (5), 477–489 quiz 489.
- Geddes, J.R., Miklowitz, D.J., 2013. Treatment of bipolar disorder. *Lancet* 381 (9878), 1672–1682.
- Gelenberg, A.J., Chesen, C.L., 2000. How fast are antidepressants? *J. Clin. Psychiatr.* 61 (10), 712–721.
- George, M.S., Lisanby, S.H., Avery, D., McDonald, W.M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., Holtzheimer 3rd, P.E., Schwartz, T., Sackeim, H.A., 2010. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. *Arch. Gen. Psychiatr.* 67 (5), 507–516.
- Glassman, A.H., Roose, S.P., 1981. Delusional depression. A distinct clinical entity? *Arch. Gen. Psychiatr.* 38 (4), 424–427.
- Gobbj, G., Ghabrash, M.F., Nunez, N., Tabaka, J., Di Sante, J., Saint-Laurent, M., Vida, S., Kolivakis, T., Low, N., Cervantes, P., Boonij, L., Comai, S., 2018. Antidepressant combination versus antidepressant plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression. *Int. Clin. Psychopharmacol.* 33 (1), 34–43.
- Goodwin, G.M., Haddad, P.M., Ferrier, I.N., Aronson, J.K., Barnes, T., Cipriani, A., Coghill, D.R., Fazel, S., Geddes, J.R., Grunze, H., Holmes, E.A., Howes, O., Hudson, S., Hunt, N., Jones, I., Macmillan, I.C., McAllister-Williams, H., Miklowitz, D.R., Morriss, R., Munafò, M., Paton, C., Saharkian, B.J., Saunders, K., Sinclair, J., Taylor, D., Vieta, E., Young, A.H., 2016. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. *J. Psychopharmacol.* 30 (6), 495–553.
- Gould, R.L., Coulson, M.C., Howard, R.J., 2012. Cognitive behavioral therapy for depression in older people: a meta-analysis and meta-regression of randomized controlled trials. *J. Am. Geriatr. Soc.* 60 (10), 1817–1830.
- Gregory Jr., V.L., 2010. Cognitive-behavioral therapy for depression in bipolar disorder: a meta-analysis. *J. Evid. Based Soc. Work* 7 (4), 269–279.
- Grunze, H., Vieta, E., Goodwin, G.M., Bowden, C., Licht, R.W., Moller, H.J., Kasper, S., WFSBP Task Force on Treatment Guidelines for Bipolar Disorders, 2013. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. *World J. Biol. Psychiatr.* 14 (3), 154–219.
- Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology. Superintendent of Documents. U.S. Government Printing Office, U.S. Department of Health, Education, and Welfare Publication, Washington, D.C No. 76-338.
- Harley, R., Sprich, S., Safren, S., Jacobo, M., Fava, M., 2008. Adaptation of dialectical behavior therapy skills training group for treatment-resistant depression. *J. Nerv. Ment. Dis.* 196 (2), 136–143.
- Hazari, H., Christman, D., Matthews, K., 2013. The clinical utility of different quantitative methods for measuring treatment resistance in major depression. *J. Affect. Disord.* 150 (2), 231–236.
- Heijnen, W.T., Birkenhager, T.K., Wiersma, A.I., van den Broek, W.W., 2010. Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: a meta-analysis. *J. Clin. Psychopharmacol.* 30 (5), 616–619.
- Holtzheimer, P.E., Husain, M.M., Lisanby, S.H., Taylor, S.F., Whitworth, L.A., McClintock, S., Slavin, K.V., Berman, J., McKhann, G.M., Patil, P.G., Rittberg, B.R., Abosch, A., Pandurang, A.K., Holloway, K.L., Lam, R.W., Honey, C.R., Neimat, J.S., Henderson, J.M., DeBattista, C., Rothschild, A.J., Pilitsis, J.G., Espinoza, R.T., Petrides, G., Mogilner, A.Y., Matthews, K., Peichel, D., Gross, R.E., Hamani, C., Lozano, A.M., Mayberg, H.S., 2017. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. *Lancet Psychiatr.* 4 (11), 839–849.
- Hsu, J.H., Mulsant, B.H., Lenze, E.J., Karp, J.F., Lavretsky, H., Roose, S.P., Reynolds 3rd, C.F., Blumberg, D.M., 2016. Impact of prior treatment on remission of late-life depression with venlafaxine and subsequent aripiprazole or placebo augmentation. *Am. J. Geriatr. Psychiatr.* 24 (10), 918–922.
- Inukai, Y., Saito, K., Sasaki, R., Tsuiki, S., Miyaguchi, S., Kojima, S., Masaki, M., Otsuru, N., Onishi, H., 2016. Comparison of three non-invasive transcranial electrical stimulation methods for increasing cortical excitability. *Front. Hum. Neurosci.* 10, 668.
- Janicak, P.G., Easton, M.S., Comaty, J.E., Dowd, S., Davis, J.M., 1989. Efficacy of ECT in psychotic and nonpsychotic depression. *Convuls. Ther.* 5, 314–320.
- Januel, D., Poirier, M.F., D'Alche-Biree, F., Dib, M., Olie, J.P., 2003. Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. *J. Affect. Disord.* 76 (1–3), 191–200.
- Joel, I., Begley, A.E., Mulsant, B.H., Lenze, E.J., Mazumdar, S., Dew, M.A., Blumberg, D., Butters, M., Reynolds 3rd, C.F., Team, I.G.I., 2014. Dynamic prediction of treatment response in late-life depression. *Am. J. Geriatr. Psychiatry* 22 (2), 167–176.
- Joffe, R.T., Sokolov, S.T., 2000. Thyroid hormone treatment of primary unipolar depression: a review. *Int. J. Neuropsychopharmacol.* 3 (2), 143–147.
- Johnston, K.M., Powell, L.C., Anderson, I.M., Szabo, S., Cline, S., 2018. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. *J. Affect. Disord.* 242, 195–210.
- Joo, J.H., Solano, F.X., Mulsant, B.H., Reynolds, C.F., Lenze, E.J., 2005. Predictors of adequacy of depression management in the primary care setting. *Psychiatr. Serv.* 56 (12), 1524–1528.
- Keller, M.B., Klerman, G.L., Lavori, P.W., Fawcett, J.A., Coryell, W., Endicott, J., 1982. Treatment received by depressed patients. *J. Am. Med. Assoc.* 248 (15), 1848–1855.
- Keller, M.B., Lavori, P.W., Klerman, G.L., Andreasen, N.C., Endicott, J., Coryell, W., Fawcett, J., Rice, J.P., Hirschfeld, R.M.A., 1986. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. *Arch. Gen. Psychiatr.* 43, 458–466.
- Kellner, C.H., Husain, M.M., Knapp, R.G., McCall, W.V., Petrides, G., Rudorfer, M.V., Young, R.C., Sampson, S., McClintock, S.M., Mueller, M., Prudic, J., Greenberg, R.M., Weiner, R.D., Bailine, S.H., Rosenquist, P.B., Raza, A., Kallio, S., Latoussakis, V., Tobias, K.G., Briggs, M.C., Liebman, L.S., Geduldig, E.T., Teklehaimanot, A.A., Lisanby, S.H., Group, C.P.W., 2016. Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study. *Am. J. Psychiatr.* 173 (11), 1101–1109.
- Klein, D., Gittelman, R., Quitkin, F., Rifkin, A., 1980. *Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children*. Williams and Wilkins, Baltimore.
- Kocsis, J.H., Gelenberg, A.J., Rothbaum, B., Klein, D.N., Trivedi, M.H., Manber, R., Keller, M.B., Howland, R., Thase, M.E., 2008. Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. *J. Affect. Disord.* 110 (1–2), 55–61.
- Kubitz, N., Mehra, M., Potluri, R.C., Garg, N., Crossow, N., 2013. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. *PLoS One* 8 (10), e76882.
- Lattanzi, L., Dell'Osso, L., Cassano, P., Pini, S., Rucci, P., Houck, P.R., Gemignani, A., Battistini, G., Bassi, A., Abelli, M., Cassano, G.B., 2002. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. *Bipolar Disord.* 4 (5), 307–314.
- Lepine, B.A., Moreno, R.A., Campos, R.N., Couttolenc, B.F., 2012. Treatment-resistant depression increases health costs and resource utilization. *Rev. Bras. Psychiatr.* 34 (4), 379–388.
- Leuchter, A.F., Cook, I.A., Hunter, A.M., Korb, A.S., 2009. A new paradigm for the prediction of antidepressant treatment response. *Dialogues Clin. Neurosci.* 11 (4), 435–446.
- Levkovitz, Y., Isserles, M., Padberg, F., Lisanby, S.H., Bystritsky, A., Xia, G., Tendler, A., Daskalakis, Z.J., Winston, J.L., Dannon, P., Hafez, H.M., Reti, I.M., Morales, O.G., Schlaepfer, T.E., Hollander, E., Berman, J.A., Husain, M.M., Sofer, U., Stein, A., Adler, S., Deutsch, L., Deutsch, F., Roth, Y., George, M.S., Zangen, A., 2015. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. *World Psychiatr.: offic. J. World Psychiatr. Assoc.* 14 (1), 64–73.
- Licht, R.W., Gijmsan, H., Nolen, W.A., Angst, J., 2008. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. *Acta Psychiatr. Scand.* 118 (5), 337–346.
- Liebowitz, M.R., Quitkin, F.M., Stewart, J.W., McGrath, P.J., Harrison, W.M., Markowitz, J.S., Rabkin, J.G., Tricamo, E., Goetz, D.M., Klein, D.F., 1988. Antidepressant specificity in atypical depression. *Arch. Gen. Psychiatr.* 45 (2), 129–137.
- Lisanby, S.H., Husain, M.M., Rosenquist, P.B., Maixner, D., Gutierrez, R., Krystal, A., Gilmer, W., Marangell, L.B., Aaronson, S., Daskalakis, Z.J., Canterbury, R., Richelson, E., Sackeim, H.A., George, M.S., 2009. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. *Neuropsychopharmacology* 34 (2), 522–534.
- Liu, B., Zhang, Y., Zhang, L., Li, L., 2014. Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study. *BMC Psychiatr.* 14, 342.
- Loo, C.K., Husain, M.M., McDonald, W.M., Aaronson, S., O'Reardon, J.P., Alonzo, A., Weickert, C.S., Martin, D.M., McClintock, S.M., Mohan, A., Lisanby, S.H., International Consortium of Research in t, D.C.S., 2018. International randomized-controlled trial of transcranial Direct Current Stimulation in depression. *Brain Stimul.* 11 (1), 125–133.
- Lynch, T.R., Whalley, B., Hempel, R.J., Byford, S., Clarke, P., Clarke, S., Kingdon, D., O'Mahen, H., Russell, I.T., Shearer, J., Stanton, M., Swales, M., Watkins, A., Remington, B., 2015. Refractory depression: mechanisms and evaluation of radically open dialectical behaviour therapy (RO-DBT) [REFRAMED]: protocol for randomised trial. *BMJ open* 5 (7), e008857.
- Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I.D., Salvatore, G., Zarate, C.A., 2010. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. *Pharmaceuticals* 3 (1), 19–41.
- Mahlich, J., Tsukazawa, S., Wiegand, F., 2018. Estimating prevalence and Healthcare utilization for treatment-resistant depression in Japan: a retrospective claims database study. *Drugs Real World Outcomes* 5 (1), 35–43.
- Malhi, G.S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P.B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., Porter, R., Singh, A.B., 2015. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust. N. Z. J. Psychiatr.* 49 (12), 1087–1206.
- Markowitz, J.C., Weissman, M.M., 2012. Interpersonal psychotherapy: past, present and

- future. *Clin. Psychol. Psychother.* 19 (2), 99–105.
- Mårtensson, B., Pettersson, A., Berglund, L., Ekselius, L., 2015. Bright white light therapy in depression: a critical review of the evidence. *J. Affect. Disord.* 182, 1–7.
- Mrazek, D.A., Hornberger, J.C., Altar, C.A., Degtjar, I., 2014. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. *Psychiatr. Serv.* 65 (8), 977–987.
- Mulsant, B.H., Haskett, R.F., Prudic, J., Thase, M.E., Malone, K.M., Mann, J.J., Pettinati, H.M., Sackeim, H.A., 1997. Low use of neuroleptic drugs in the treatment of psychotic major depression. *Am. J. Psychiatry* 154 (4), 559–561.
- Muzina, D.J., Calabrese, J.R., 2003. Recent placebo-controlled acute trials in bipolar depression: focus on methodology. *Int. J. Neuropsychopharmacol.* 6 (3), 285–291.
- Nelson, J.C., Baumann, P., Delucchi, K., Joffe, R., Katona, C., 2014. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. *J. Affect. Disord.* 168, 269–275.
- Nelson, J.C., Papakostas, G.I., 2009. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. *Am. J. Psychiatr.* 166 (9), 980–991.
- Nelson, J.C., Price, L.H., Jatlow, P.I., 1986. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. *Am. J. Psychiatr.* 143 (9), 1151–1154.
- Nierenberg, A.A., McLean, N.E., Alpert, J.E., Worthington, J.J., Rosenbaum, J.F., Fava, M., 1995. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. *Am. J. Psychiatr.* 152 (10), 1500–1503.
- O'Reardon, J.P., Solvason, H.B., Janicak, P.G., Sampson, S., Isenberg, K.E., Nahas, Z., McDonald, W.M., Avery, D., Fitzgerald, P.B., Loo, C., Demitrack, M.A., George, M.S., Sackeim, H.A., 2007. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. *Biol. Psychiatr.* 62 (11), 1208–1216.
- Olson, M., Amos, T.B., Benson, C., McRae, J., Marcus, S.C., 2018. Prospective service use and health care costs of medicaid beneficiaries with treatment-resistant depression. *J. Manag. Care Spec. Pharm.* 24 (3), 226–236.
- Oquendo, M.A., Baca-Garcia, E., Kartachov, A., Khait, V., Campbell, C.E., Richards, M., Sackeim, H.A., Prudic, J., Mann, J.J., 2003. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. *J. Clin. Psychiatr.* 64 (7), 825–833.
- Oquendo, M.A., Kamali, M., Ellis, S.P., Grunebaum, M.F., Malone, K.M., Brodsky, B.S., Sackeim, H.A., Mann, J.J., 2002. Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. *Am. J. Psychiatr.* 159 (10), 1746–1751.
- Oquendo, M.A., Malone, K.M., Ellis, S.P., Sackeim, H.A., Mann, J.J., 1999. Antidepressant treatment is inadequate in patients with major depression who are at risk for suicidal behavior. *Am. J. Psychiatr.* 156, 190–194.
- Pacchiarotti, I., Bond, D.J., Baldessarini, R.J., Nolen, W.A., Grunze, H., Licht, R.W., Post, R.M., Berk, M., Goodwin, G.M., Sachs, G.S., Tondo, L., Findling, R.L., Youngstrom, E.A., Tohen, M., Undurraga, J., Gonzalez-Pinto, A., Goldberg, J.F., Yildiz, A., Altshuler, L.L., Calabrese, J.R., Mitchell, P.B., Thase, M.E., Koukopoulos, A., Colom, F., Frye, M.A., Malhi, G.S., Fountoulakis, K.N., Vazquez, G., Perlis, R.H., Ketter, T.A., Cassidy, F., Akiskal, H., Azorin, J.M., Valenti, M., Mazzei, D.H., Lafer, B., Kato, T., Mazzarini, L., Martinez-Aran, A., Parker, G., Souery, D., Ozerdem, A., McElroy, S.L., Girardi, P., Bauer, M., Yatham, L.N., Zarate, C.A., Nierenberg, A.A., Birmaher, B., Kanba, S., El-Mallakh, R.S., Serretti, A., Rihmer, Z., Young, A.H., Kotzalidis, G.D., MacQueen, G.M., Bowden, C.L., Ghaemi, S.N., Lopez-Jaramillo, C., Rybakowski, J., Ha, K., Perugi, G., Kasper, S., Amstutz, J.D., Hirschfeld, R.M., Kapczynski, F., Vieta, E., 2013. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. *Am. J. Psychiatr.* 170 (11), 1249–1262.
- Papakostas, G.I., Perlis, R.H., Scalia, M.J., Petersen, T.J., Fava, M., 2006. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. *J. Clin. Psychopharmacol.* 26 (1), 56–60.
- Papakostas, G.I., Shelton, R.C., Smith, J., Fava, M., 2007. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. *J. Clin. Psychiatr.* 68 (6), 826–831.
- Peeters, F.P., Ruhe, H.G., Wichers, M., Abidi, L., Kaub, K., van der Lande, H.J., Spijker, J., Huibers, M.J., Schene, A.H., 2016. The Dutch measure for quantification of treatment resistance in depression (DM-TRD): an extension of the Maudsley staging method. *J. Affect. Disord.* 205, 365–371.
- Petrides, G., Fink, M., Husain, M.M., Knapp, R.G., Rush, A.J., Mueller, M., Rummans, T.A., O'Connor, K.M., Rasmussen Jr., K.G., Bernstein, H.J., Biggs, M., Bailine, S.H., Kellner, C.H., 2001. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. *J. ECT* 17 (4), 244–253.
- Philip, N.S., Carpenter, L.L., Tyrka, A.R., Price, L.H., 2010. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. *Expert Opin. Pharmacother.* 11 (5), 709–722.
- Prudic, J., Haskett, R.F., McCall, W.V., Isenberg, K., Cooper, T., Rosenquist, P.B., Mulsant, B.H., Sackeim, H.A., 2013. Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. *J. ECT* 29 (1), 3–12.
- Prudic, J., Haskett, R.F., Mulsant, B., Malone, K.M., Pettinati, H.M., Dtephens, S., Greenberg, R., Rifas, S.L., Sackeim, H.A., 1996. Resistance to antidepressant medications and short-term clinical response to ECT. *Am. J. Psychiatr.* 153 (8), 985–992.
- Prudic, J., Sackeim, H.A., Devanand, D.P., 1990. Medication resistance and clinical response to electroconvulsive therapy. *Psychiatr. Res.* 31 (3), 287–296.
- Quitkin, F.M., Stewart, J.W., McGrath, P.J., Liebowitz, M.R., Harrison, W.M., Tricamo, E., Klein, D.F., Rabkin, J.G., Markowitz, J.S., Wager, S.G., 1988. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. *Am. J. Psychiatr.* 145 (3), 306–311.
- Rasmussen, K.G., Mueller, M., Knapp, R.G., Husain, M.M., Rummans, T.A., Sampson, S.M., O'Connor, M.K., Petrides, G., Fink, M., Kellner, C.H., 2007. Antidepressant medication treatment failure does not predict lower remission with ECT for major depressive disorder: a report from the consortium for research in electroconvulsive therapy. *J. Clin. Psychiatr.* 68 (11), 1701–1706.
- Rasmussen, K.G., Mueller, M., Rummans, T.A., Husain, M.M., Petrides, G., Knapp, R.G., Fink, M., Sampson, S.M., Bailine, S.H., Kellner, C.H., 2009. Is baseline medication resistance associated with potential for relapse after successful remission of a depressive episode with ECT? Data from the Consortium for Research on Electroconvulsive Therapy (CORE). *J. Clin. Psychiatr.* 70 (2), 232–237.
- Reutfofs, J., Andersson, T.M., Brenner, P., Brandt, L., DiBernardo, A., Li, G., Hagg, D., Wingard, L., Boden, R., 2018. Mortality in treatment-resistant unipolar depression: a register-based cohort study in Sweden. *J. Affect. Disord.* 238, 674–679.
- Rizvi, S.J., Grima, E., Tan, M., Rotzinger, S., Lin, P., McIntyre, R.S., Kennedy, S.H., 2014. Treatment-resistant depression in primary care across Canada. *Can. J. Psychiatr.* 59 (7), 349–357.
- Ruhe, H.G., van Rooijen, G., Spijker, J., Peeters, F.P., Schene, A.H., 2012. Staging methods for treatment resistant depression. A systematic review. *J. Affect. Disord.* 137 (1–3), 35–45.
- Rush, A.J., Fava, M., Wisniewski, S.R., Lavori, P.W., Trivedi, M.H., Sackeim, H.A., Thase, M.E., Nierenberg, A.A., Quitkin, F.M., Kashner, T.M., Kupfer, D.J., Rosenbaum, J.F., Alpert, J., Stewart, J.W., McGrath, P.J., Biggs, M.M., Shores-Wilson, K., Lebowitz, B.D., Ritz, L., Niederehe, G., Group, S.D.I., 2004. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. *Contr. Clin. Trials* 25 (1), 119–142.
- Rush, A.J., Kraemer, H.C., Sackeim, H.A., Fava, M., Trivedi, M.H., Frank, E., Ninan, P.T., Thase, M.E., Gelenberg, A.J., Kupfer, D.J., Regier, D.A., Rosenbaum, J.F., Ray, O., Schatzberg, A.F., 2006a. Report by the ACNP Task Force on response and remission in major depressive disorder. *Neuropsychopharmacology* 31 (9), 1841–1853.
- Rush, A.J., Marangell, L.B., Sackeim, H.A., George, M.S., Brannan, S.K., Davis, S.M., Howland, R., Kling, M.A., Rittberg, B.R., Burke, W.J., Rapaport, M.H., Zajecka, J., Nierenberg, A.A., Husain, M.M., Ginsberg, D., Cooke, R.G., 2005a. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. *Biol. Psychiatr.* 58 (5), 347–354.
- Rush, A.J., Sackeim, H.A., Marangell, L.B., George, M.S., Brannan, S.K., Davis, S.M., Lavori, P., Howland, R., Kling, M.A., Rittberg, B., Carpenter, L., Ninan, P., Moreno, F., Schwartz, T., Conway, C., Burke, M., Barry, J.J., 2005b. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. *Biol. Psychiatr.* 58 (5), 355–363.
- Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M., 2006b. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am. J. Psychiatr.* 163 (11), 1905–1917.
- Russell, J.M., Hawkins, K., Ozminkowski, R.J., Orsini, L., Crown, W.H., Kennedy, S., Finkelstein, S., Berndt, E., Rush, A.J., 2004. The cost consequences of treatment-resistant depression. *J. Clin. Psychiatr.* 65 (3), 341–347.
- Sachs, G.S., Nierenberg, A.A., Calabrese, J.R., Marangell, L.B., Wisniewski, S.R., Gyulai, L., Friedman, E.S., Bowden, C.L., Fossey, M.D., Ostacher, M.J., Ketter, T.A., Patel, J., Hauser, P., Rapport, D., Martinez, J.M., Allen, M.H., Miklowitz, D.J., Otto, M.W., Dennehy, E.B., Thase, M.E., 2007. Effectiveness of adjunctive antidepressant treatment for bipolar depression. *N. Engl. J. Med.* 356 (17), 1711–1722.
- Sackeim, H.A., 2001. The definition and meaning of treatment-resistant depression. *J. Clin. Psychiatr.* 62 (Suppl. 16), 10–17.
- Sackeim, H.A., Brannan, S.K., Rush, A.J., George, M.S., Marangell, L.B., Allen, J., 2007. Durability of antidepressant response to vagus nerve stimulation (VNS). *Int. J. Neuropsychopharmacol.* 10 (6), 817–826.
- Sackeim, H.A., Dillingham, E.M., Prudic, J., Cooper, T., McCall, W.V., Rosenquist, P., Isenberg, K., Garcia, K., Mulsant, B.H., Haskett, R.F., 2009. Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. *Arch. Gen. Psychiatr.* 66 (7), 729–737.
- Sackeim, H.A., Haskett, R.F., Mulsant, B.H., Thase, M.E., Mann, J.J., Pettinati, H.M., Greenberg, R.M., Crowe, R.R., Cooper, T.B., Prudic, J., 2001a. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. *J. Am. Med. Assoc.* 285 (10), 1299–1307.
- Sackeim, H.A., Prudic, J., 2005. Length of the ECT course in bipolar and unipolar depression. *J. ECT* 21 (3), 195–197.
- Sackeim, H.A., Prudic, J., Devanand, D.P., Decina, P., Kerr, B., Malitz, S., 1990. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. *J. Clin. Psychopharmacol.* 10 (2), 96–104.
- Sackeim, H.A., Prudic, J., Devanand, D.P., Kiersky, J.E., Fitzsimons, L., Moody, B.J., McElhiney, M.C., Coleman, E.A., Settembrino, J.M., 1993. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. *N. Engl. J. Med.* 328 (12), 839–846.
- Sackeim, H.A., Prudic, J., Devanand, D.P., Nobler, M.S., Lisanby, S.H., Peyser, S., Fitzsimons, L., Moody, B.J., Clark, J., 2000. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. *Arch. Gen. Psychiatr.* 57 (5), 425–434.
- Sackeim, H.A., Prudic, J., Nobler, M.S., Fitzsimons, L., Lisanby, S.H., Payne, N., Berman, R.M., Brakemeier, E.L., Perera, T., Devanand, D.P., 2008. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. *Brain Stimul.* 1 (2), 71–83.
- Sackeim, H.A., Roose, S.P., Lavori, P.W., 2006. Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD). *Biol. Psychiatr.* 59 (6), 483–492.
- Sackeim, H.A., Rush, A.J., George, M.S., Marangell, L.B., Husain, M.M., Nahas, Z.,

- Johnson, C.R., Seidman, S., Giller, C., Haines, S., Simpson Jr., R.K., Goodman, R.R., 2001b. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. *Neuropsychopharmacology* 25 (5), 713–728.
- Sackeim, H.A., Rush, A.J., George, M.S., Marangell, L.B., Husain, M.M., Nahas, Z., Johnson, C.R., Seidman, S., Giller, C., Haines, S., Simpson Jr., R.K., Goodman, R.R., 2001c. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. *Neuropsychopharmacology* 25 (5), 713–728.
- Sanacora, G., Frye, M.A., McDonald, W., Mathew, S.J., Turner, M.S., Schatzberg, A.F., Summergrad, P., Nemeroff, C.B., American Psychiatric Association Council of Research Task Force on Novel, B., Treatments, 2017. A consensus statement on the use of ketamine in the treatment of mood disorders. *JAMA Psychiatr.* 74 (4), 399–405.
- Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G.I., Fava, M., Berk, M., Ng, C.H., 2016. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. *Am. J. Psychiatr.* 173 (6), 575–587.
- Saveanu, R., Etkin, A., Duchemin, A., Goldstein-Piekarski, A., Gyurak, A., Debattista, C., Schatzberg, A., Sood, S., Day, C., Palmer, D., Rekshan, W., Gordon, E., Rush, A., Williams, L., 2015. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. *J. Psychiatr. Res.* 61, 1–12.
- Schule, C., Baghai, T.C., Eser, D., Nothdurfter, C., Rupprecht, R., 2009. Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: an open-label study. *World J. Biol. Psychiatr.* 10 (4 Pt 2), 390–399.
- Semkovska, M., Landau, S., Dunne, R., Kolshus, E., Kavanagh, A., Jelovac, A., Noone, M., Carton, M., Lambe, S., McHugh, C., McLoughlin, D.M., 2016. Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomized, non-inferiority trial. *Am. J. Psychiatr.* 173 (4), 408–417.
- Sidor, M.M., Macqueen, G.M., 2011. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. *J. Clin. Psychiatr.* 72 (2), 156–167.
- Sienaert, P., Vansteelandt, K., Demyttenaere, K., Peuskens, J., 2009. Ultra-brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of response. *Bipolar Disord.* 11 (4), 418–424.
- Simons, P., Cosgrove, L., Shaughnessy, A.F., Bursztajn, H., 2017. Antipsychotic augmentation for major depressive disorder: a review of clinical practice guidelines. *Int. J. Law Psychiatry* 55, 64–71.
- Singh, J.B., Fedgchin, M., Daly, E.J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrrough, J.W., Sanacora, G., Shelton, R.C., Kurian, A., Fava, M., Manji, H., Drevets, W.C., Van Nueten, L., 2016. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. *Am. J. Psychiatr.* 173 (8), 816–826.
- Sobin, C., Prudic, J., Devanand, D.P., Nobler, M.S., Sackeim, H.A., 1996. Who responds to electroconvulsive therapy? A comparison of effective and ineffective forms of treatment. *Br. J. Psychiatry* 169 (3), 322–328.
- Solan, W.J., Khan, A., Avery, D.H., Cohen, S., 1988. Psychotic and nonpsychotic depression: comparison of response to ECT. *J. Clin. Psychiatr.* 49 (3), 97–99.
- Souery, D., Amsterdam, J., de Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., Racagni, G., Zohar, J., Mendlewicz, J., 1999. Treatment resistant depression: methodological overview and operational criteria. *Eur. Neuropsychopharmacol.* 9 (1–2), 83–91.
- Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., Zohar, J., Mendlewicz, J., Group for the Study of Resistant, D., 2007. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. *J. Clin. Psychiatr.* 68 (7), 1062–1070.
- Souza, L.H., Salum, G.A., Mosquero, B.P., Caldieraro, M.A., Guerra, T.A., Fleck, M.P., 2016. Interpersonal psychotherapy as add-on for treatment-resistant depression: a pragmatic randomized controlled trial. *J. Affect. Disord.* 193, 373–380.
- Spiker, D.G., Weiss, J.C., Dealy, R.S., Griffin, S.J., Hanin, I., Neil, J.F., Perel, J.M., Rossi, A.J., Soloff, P.H., 1985. The pharmacological treatment of delusional depression. *Am. J. Psychiatry* 142 (4), 430–436.
- Suppes, T., Rush, A.J., 1996. Medication optimization during clozapine treatment. *J. Clin. Psychiatr.* 57 (7), 307–308.
- Suppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., Rush, A.J., 1999. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. *Am. J. Psychiatr.* 156 (8), 1164–1169.
- Szegedi, A., Jansen, W.T., van Willigenburg, A.P., van der Meulen, E., Stassen, H.H., Thase, M.E., 2009. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. *J. Clin. Psychiatr.* 70 (3), 344–353.
- Targum, S.D., 2014. Identification and treatment of antidepressant tachyphylaxis. *Innov. Clin Neurosci* 11 (3–4), 24–28.
- Thase, M.E., 2009. Pharmacologic and therapeutic strategies in treatment-resistant depression. *Augmentation strategies.* *CNS Spectr.* 14 (3 Suppl. 4), 7–10.
- Thase, M.E., 2011. Treatment-resistant depression: prevalence, risk factors, and treatment strategies. *J. Clin. Psychiatr.* 72 (5), e18.
- Thase, M.E., Rush, A.J., 1995. Treatment-resistant depression. In: Bloom, F., Kupfer, D. (Eds.), *Psychopharmacology: the Fourth Generation of Progress.* Raven, New York, pp. 1081–1098.
- Thase, M.E., Rush, A.J., 1997. When at first you don't succeed: sequential strategies for antidepressant nonresponders. *J. Clin. Psychiatry* 58 (Suppl. 13), 23–29.
- Thase, M.E., Sachs, G.S., 2000. Bipolar depression: pharmacotherapy and related therapeutic strategies. *Biol. Psychiatr.* 48 (6), 558–572.
- Thomas, L., Kessler, D., Campbell, J., Morrison, J., Peters, T.J., Williams, C., Lewis, G., Wiles, N., 2013. Prevalence of treatment-resistant depression in primary care: cross-sectional data. *Br. J. Gen. Pract.* 63 (617), e852–858.
- Tolin, D.F., 2017. Can cognitive behavioral therapy for anxiety and depression Be improved with pharmacotherapy? A meta-analysis. *Psychiatr. Clin.* 40 (4), 715–738.
- Town, J.M., Abbass, A., Stride, C., Bernier, D., 2017. A randomised controlled trial of intensive short-term dynamic psychotherapy for treatment resistant depression: the halifax depression study. *J. Affect. Disord.* 214, 15–25.
- Townsend, E., Hawton, K., Altman, D.G., Arensman, E., Gunnell, D., Hazell, P., House, A., Van Heeringen, K., 2001. The efficacy of problem-solving treatments after deliberate self-harm: meta-analysis of randomized controlled trials with respect to depression, hopelessness and improvement in problems. *Psychol. Med.* 31 (6), 979–988.
- Trevino, K., McClintock, S.M., McDonald Fischer, N., Vora, A., Husain, M.M., 2014. Defining treatment-resistant depression: a comprehensive review of the literature. *Ann. Clin. Psychiatr.* 26 (3), 222–232.
- Trivedi, R.B., Nieuwsma, J.A., Williams Jr., J.W., 2011. Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. *J. Gen. Intern. Med.* 26 (6), 643–650.
- Tuunainen, A., Kripke, D.F., Endo, T., 2004. Light therapy for non-seasonal depression. *Cochrane Database Syst. Rev.* 2, CD004050.
- van Belkum, S.M., Geugies, H., Lysen, T.S., Cleare, A.J., Peeters, F., Penninx, B., Schoevers, R.A., Ruhe, H.G., 2018. Validity of the Maudsley staging method in predicting treatment-resistant depression outcome using The Netherlands study of depression and anxiety. *J. Clin. Psychiatr.* 79 (1).
- van Bronswijk, S., Moopen, N., Beijers, L., Ruhe, H.G., Peeters, F., 2018. Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression. *Psychol. Med.* 1–14.
- van den Broek, W.W., de Lely, A., Mulder, P.G., Birkenhager, T.K., Bruijn, J.A., 2004. Effect of antidepressant medication resistance on short-term response to electroconvulsive therapy. *J. Clin. Psychopharmacol.* 24 (4), 400–403.
- Vazquez, G., Tondo, L., Baldessarini, R.J., 2011. Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: a meta-analytic review. *Pharmacopsychiatr.* 44 (1), 21–26.
- Vazquez, G.H., Tondo, L., Undurraga, J., Baldessarini, R.J., 2013. Overview of antidepressant treatment of bipolar depression. *Int. J. Neuropsychopharmacol.* 16 (7), 1673–1685.
- Wang, H.R., Woo, Y.S., Ahn, H.S., Ahn, I.M., Kim, H.J., Bahk, W.M., 2015. Can atypical antipsychotic augmentation reduce subsequent treatment failure more effectively among depressed patients with a higher degree of treatment resistance? A meta-analysis of randomized controlled trials. *Int. J. Neuropsychopharmacol.* 18 (8).
- Weissman, M.M., Hankerson, S.H., Scorza, P., Olfson, M., Verdelli, H., Shea, S., Lantigua, R., Wainberg, M., 2014. Interpersonal counseling (IPC) for depression in primary care. *Am. J. Psychother.* 68 (4), 359–383.
- Wijeratne, C., Sachdev, P., 2008. Treatment-resistant depression: critique of current approaches. *Aust. N. Z. J. Psychiatr.* 42 (9), 751–762.
- Wijkstra, J., Burger, H., van den Broek, W.W., Birkenhager, T.K., Janzing, J.G., Boks, M.P., Bruijn, J.A., van der Loos, M.L., Breteler, L.M., Ramaekers, G.M., Verkes, R.J., Nolen, W.A., 2010. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. *Acta Psychiatr. Scand.* 121 (3), 190–200.
- Wijkstra, J., Lijmer, J., Burger, H., Cipriani, A., Geddes, J., Nolen, W.A., 2015. Pharmacological treatment for psychotic depression. *Cochrane Database Syst. Rev.* 7, CD004044.
- Wilkinson, S.T., Ballard, E.D., Bloch, M.H., Mathew, S.J., Murrrough, J.W., Feder, A., Sos, P., Wang, G., Zarate Jr., C.A., Sanacora, G., 2018. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. *Am. J. Psychiatry* 175 (2), 150–158.
- Zhou, X., Ravindran, A.V., Qin, B., Del Giovane, C., Li, Q., Bauer, M., Liu, Y., Fang, Y., da Silva, T., Zhang, Y., Fang, L., Wang, X., Xie, P., 2015. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. *J. Clin. Psychiatry* 76 (4), e487–498.